WELL Health Technologies Corp (WELL) AI Stock Analysis

• Market Cap: C$1.26B
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 20.36%
• EPS Growth: -186.10%
• Country: CA
• Employees: 1,507
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.16
• Shares Outstanding: 253,894,040
• 10 Day Avg. Volume: 1,712,971
• 30 Day Avg. Volume: 1,366,290
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.58
• Price Target Upside: 54.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$5.00 ▲(2.04% Upside)

The overall stock score is primarily influenced by the company's strong revenue growth, which is offset by significant challenges in profitability and cash flow management. Technical analysis suggests mixed signals, with potential for a longer-term uptrend despite short-term bearish momentum. The valuation is negatively impacted by the company's unprofitability and lack of dividend yield.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates a successful expansion of its market presence and product adoption, which is crucial for long-term sustainability and competitiveness in the healthcare technology sector.

Diverse Revenue Streams

WELL's diverse revenue streams from clinics, digital solutions, and telehealth provide a stable financial base, reducing reliance on any single source and enhancing resilience against market fluctuations.

Strategic Partnerships

Strategic partnerships with healthcare and tech firms enhance WELL's service offerings and market reach, supporting long-term growth and competitive positioning in the healthcare technology industry.

Negative Factors

Profitability Challenges

Ongoing profitability challenges, indicated by negative net profit and EBIT margins, could hinder WELL's ability to reinvest in growth opportunities and maintain financial health over the long term.

Cash Flow Issues

Negative free cash flow suggests difficulties in generating sufficient cash from operations, which could limit WELL's ability to fund new initiatives or weather economic downturns.

Decreasing Gross Profit Margin

A decreasing gross profit margin indicates potential inefficiencies in cost management, which could impact WELL's ability to sustain profitability and competitive pricing in the long run.

WELL Health Technologies Corp Business Overview & Revenue Model

Company Description

WELL Health Technologies Corp (WELL) is a Vancouver-based digital health company focused on empowering healthcare providers and patients through innovative technology solutions. The company operates primarily in the healthcare sector, offering a range of services that include telehealth, electronic medical records (EMR) solutions, and patient engagement platforms. WELL's core products aim to enhance access to healthcare, streamline clinical workflows, and improve patient outcomes, making it a key player in the digital transformation of healthcare services.

How the Company Makes Money

WELL Health generates revenue through multiple streams, primarily by providing software and technology solutions to healthcare providers. Key revenue sources include subscription fees for its EMR systems, transaction fees from telehealth consultations, and sales of patient engagement tools. Additionally, WELL benefits from partnerships with various healthcare organizations and institutions, which enable it to expand its service offerings and reach a broader customer base. The company also explores opportunities in acquisitions to enhance its technology portfolio and increase market share, contributing to its overall earnings.

WELL Health Technologies Corp Financial Statement Overview

Summary

WELL Health Technologies Corp shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is stable, but negative profitability and cash flow conversion issues need addressing.

Income Statement

WELL Health Technologies Corp has shown a positive revenue growth rate of 11.56% in the TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased over time, reflecting potential cost management issues.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.57, suggesting a balanced approach to leveraging. However, the negative return on equity in the TTM indicates challenges in generating returns for shareholders. The equity ratio is stable, showing a solid capital structure.

Cash Flow

The cash flow statement reveals a significant improvement in free cash flow growth rate, but the free cash flow remains negative. The operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.10B	919.69M	776.05M	569.14M	302.32M	50.24M
Gross Profit	429.62M	363.01M	372.27M	303.29M	153.69M	21.22M
EBITDA	-19.20M	122.52M	101.88M	95.99M	21.27M	-495.00K
Net Income	-128.62M	32.61M	82.00K	19.07M	-30.69M	-2.62M
Balance Sheet
Total Assets	2.02B	1.81B	1.41B	1.32B	1.26B	262.73M
Cash, Cash Equivalents and Short-Term Investments	98.89M	131.67M	43.42M	48.91M	61.92M	86.89M
Total Debt	569.76M	425.09M	426.28M	358.42M	401.94M	23.57M
Total Liabilities	1.03B	877.55M	563.16M	503.78M	554.37M	43.75M
Stockholders Equity	826.20M	867.61M	767.67M	732.34M	618.24M	217.37M
Cash Flow
Free Cash Flow	-17.33M	-6.70M	37.20M	70.14M	19.59M	-6.52M
Operating Cash Flow	3.93M	9.52M	66.44M	76.55M	22.27M	-5.38M
Investing Cash Flow	-86.18M	-60.23M	-106.42M	-37.93M	-499.78M	-44.21M
Financing Cash Flow	133.09M	133.50M	10.63M	-52.85M	452.53M	120.84M

WELL Health Technologies Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.90
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Negative. The current price of 4.9 is below the 20-day moving average (MA) of 5.15, below the 50-day MA of 5.02, and above the 200-day MA of 4.83, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.99 is Neutral, neither overbought nor oversold. The STOCH value of 27.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DNTL	64 Neutral	C$2.17B	-46.32	-2.58%	0.69%	9.94%	35.48%
DR	63 Neutral	C$259.74M	2.03	41.13%	2.54%	-35.35%	948.72%
CRRX	56 Neutral	C$229.69M	3,650.00	0.11%	0.55%	0.19%	―
NLH	55 Neutral	C$26.19M	157.89	0.69%	―	11.89%	5.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WELL	48 Neutral	C$1.26B	-9.60	-14.61%	―	20.36%	-186.10%

WELL Health Technologies Corp Corporate Events

WELL Health Technologies to Release Q3 2025 Financial Results

WELL Health Technologies Corp. announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025. The company will hold a conference call and webcast on the same day to discuss the results, which could provide insights into its operational performance and market positioning.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

WELL Health Technologies Achieves Record Q2-2025 Results and Milestone Patient Visits

WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.